{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:02:12Z","timestamp":1793239332985,"version":"4.5.0"},"reference-count":109,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>ABSTRACT<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is a dermatological disease that causes nonscarring hair loss. It can occur at any age and has an unpredictable and variable evolution in individuals. The aim of this review is to provide an update on the novel therapies currently being used, as well as upcoming therapeutic options in the treatment of AA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijt.ijt_28_21","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:23:59Z","timestamp":1681950239000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":50,"title":["An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options"],"prefix":"10.4103","volume":"15","author":[{"given":"Karan","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Madke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240903","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: An Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"key":"R2-2-20240903","first-page":"e404","article-title":"Alopecia areata. Current situation and perspectives","volume":"115","author":"Ju\u00e1rez-Rend\u00f3n","year":"2017","journal-title":"Arch Argent Pediatr"},{"key":"R3-2-20240903","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1067\/mjd.2000.103909","article-title":"Alopecia areata update","volume":"42","author":"Madani","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R4-2-20240903","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000254503","article-title":"A new classification of alopecia areata","volume":"131","author":"Ikeda","year":"1965","journal-title":"Dermatology"},{"key":"R6-2-20240903","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1525-1470.2002.00088.x","article-title":"A clinical study of childhood alopecia areata in Singapore","volume":"19","author":"Tan","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"R7-2-20240903","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mjd.2003.423","article-title":"Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis","volume":"49","author":"Tosti","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R8-2-20240903","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0019-5154.62747","article-title":"Comparative assessment of topical steroids, topical tretenoin (0.05%) and dithranol paste in alopecia areata","volume":"55","author":"Das","year":"2010","journal-title":"Indian J Dermatol"},{"key":"R9-2-20240903","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.det.2004.09.008","article-title":"Management of hair loss","volume":"23","author":"Ross","year":"2005","journal-title":"Dermatol Clin"},{"key":"R10-2-20240903","first-page":"674","article-title":"Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs","volume":"71","author":"Kubeyinje","year":"1994","journal-title":"East Afr Med J"},{"key":"R11-2-20240903","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0974-7753.66920","article-title":"Intralesional steroids for alopecia areata","volume":"2","author":"Kumaresan","year":"2010","journal-title":"Int J Trichology"},{"key":"R12-2-20240903","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM199909233411307","article-title":"Treatment of hair loss","volume":"341","author":"Price","year":"1999","journal-title":"N Engl J Med"},{"key":"R13-2-20240903","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/0378-6323.110767","article-title":"Dermoscopic evaluation of therapeutic response to an intralesional corticosteroid in the treatment of alopecia areata","volume":"79","author":"Ganjoo","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R14-2-20240903","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0733-8635(05)70400-9","article-title":"Topical immunotherapy in alopecia areata. What, how, and why?","volume":"14","author":"Hoffmann","year":"1996","journal-title":"Dermatol Clin"},{"key":"R15-2-20240903","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0190-9622(98)70048-9","article-title":"Efficacy of topical sensitizers in the treatment of alopecia areata","volume":"39","author":"Rokhsar","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"R16-2-20240903","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1525-1470.1994.tb00078.x","article-title":"Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients","volume":"11","author":"Orecchia","year":"1994","journal-title":"Pediatr Dermatol"},{"key":"R17-2-20240903","doi-asserted-by":"crossref","first-page":"e13010","DOI":"10.1111\/dth.13010","article-title":"Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin","volume":"32","author":"Ibrahim","year":"2019","journal-title":"Dermatol Ther"},{"key":"R19-2-20240903","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.alit.2019.10.008","article-title":"Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients","volume":"69","author":"Sakai","year":"2020","journal-title":"Allergol Int"},{"key":"R20-2-20240903","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4103\/0378-6323.42924","article-title":"Topical dinitrochlorobenzene (DNCB) for alopecia areata: Revisited","volume":"74","author":"Mohan","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R21-2-20240903","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00403-019-01940-x","article-title":"Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: A retrospective case series","volume":"311","author":"Nasimi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"R22-2-20240903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.0906-6705.2004.00098.x","article-title":"Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin","volume":"13","author":"Tang","year":"2004","journal-title":"Exp Dermatol"},{"key":"R23-2-20240903","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-4362.1985.tb05863.x","article-title":"Anthralin therapy for alopecia areata","volume":"24","author":"Nelson","year":"1985","journal-title":"Int J Dermatol"},{"key":"R24-2-20240903","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archderm.1987.01660350091020","article-title":"Evaluation of anthralin in the treatment of alopecia areata","volume":"123","author":"Fiedler-Weiss","year":"1987","journal-title":"Arch Dermatol"},{"key":"R25-2-20240903","first-page":"641","article-title":"Therapeutic effect of topical anthralin for treatment-resistant extensive alopecia areata","volume":"46","author":"Wong","year":"2008","journal-title":"Korean J Dermatol"},{"key":"R26-2-20240903","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/bmj.287.6398.1015","article-title":"Topical minoxidil in the treatment of alopecia areata","volume":"287","author":"Fenton","year":"1983","journal-title":"Br Med J (Clin Res Ed"},{"key":"R27-2-20240903","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.18203\/2320-6012.ijrms20201310","article-title":"Does microneedling with 5% minoxidil offer added advantage for treatment of androgenetic alopecia in comparison to use of topical 5% minoxidil alone?","volume":"8","author":"Malhotra","year":"2020","journal-title":"Int J Res Med Sci"},{"key":"R28-2-20240903","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archderm.1990.01670300056006","article-title":"Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin","volume":"126","author":"Fiedler","year":"1990","journal-title":"Arch Dermatol"},{"key":"R29-2-20240903","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1111\/1523-1747.ep12471880","article-title":"Alopecia areata: Current therapy","volume":"96","author":"Fiedler","year":"1991","journal-title":"J Invest Dermatol"},{"key":"R30-2-20240903","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/archderm.1992.01680210045005","article-title":"Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata","volume":"128","author":"Olsen","year":"1992","journal-title":"Arch Dermatol"},{"key":"R31-2-20240903","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.2147\/DDDT.S214907","article-title":"Minoxidil and its use in hair disorders: A review","volume":"13","author":"Suchonwanit","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R32-2-20240903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dth.12437","article-title":"Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation","volume":"30","author":"El Taieb","year":"2017","journal-title":"Dermatol Ther"},{"key":"R33-2-20240903","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2004.05.019","article-title":"Topical tacrolimus in alopecia areata","volume":"52","author":"Price","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R34-2-20240903","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/1523-1747.ep12606018","article-title":"Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant","volume":"104","author":"Jiang","year":"1995","journal-title":"J Invest Dermatol"},{"key":"R35-2-20240903","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.jaad.2009.02.037","article-title":"Phase I\/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata","volume":"61","author":"Talpur","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R36-2-20240903","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2008.08.029","article-title":"Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata","volume":"60","author":"Roseborough","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R37-2-20240903","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1468-3083.2009.03543.x","article-title":"Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis","volume":"24","author":"Coronel-Perez","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R38-2-20240903","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2340\/000155555493496","article-title":"Large doses of glucocorticoid in the treatment of alopecia areata","volume":"55","author":"Burton","year":"1975","journal-title":"Acta Derm Venereol"},{"key":"R39-2-20240903","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-4362.1996.tb03281.x","article-title":"Pulsed administration of corticosteroids in the treatment of alopecia areata","volume":"35","author":"Sharma","year":"1996","journal-title":"Int J Dermatol"},{"key":"R40-2-20240903","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.annder.2010.06.002","article-title":"Treatment of alopecia areata with prednisolone in a once-monthly oral pulse","volume":"137","author":"Ait Ourhroui","year":"2010","journal-title":"Ann Dermatol Venereol"},{"key":"R41-2-20240903","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1346-8138.1999.tb02049.x","article-title":"Twice weekly 5-mg dexamethasone oral pulse in the treatment of extensive alopecia areata","volume":"26","author":"Sharma","year":"1999","journal-title":"J Dermatol"},{"key":"R42-2-20240903","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/0019-5154.53185","article-title":"Childhood vitiligo: Response to methylprednisolone oral minipulse therapy and topical fluticasone combination","volume":"54","author":"Majid","year":"2009","journal-title":"Indian J Dermatol"},{"key":"R43-2-20240903","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","article-title":"Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease","volume":"32","author":"Pasricha","year":"1993","journal-title":"Int J Dermatol"},{"key":"R44-2-20240903","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/ijd.IJD_481_16","article-title":"Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata","volume":"64","author":"Gupta","year":"2019","journal-title":"Indian J Dermatol"},{"key":"R45-2-20240903","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jaad.2015.12.055","article-title":"Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine","volume":"74","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R46-2-20240903","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/ijt.ijt_57_19","article-title":"Alopecia areata treated with oral azathioprine: A case series","volume":"11","author":"Saoji","year":"2019","journal-title":"Int J Trichology"},{"key":"R47-2-20240903","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annder.2010.06.031","article-title":"Long-term follow-up of the efficacy of methotrexate alone or in combination with low dose of oral corticosteroids in the treatment of alopecia totalis or universalis","volume":"137","author":"Chartaux","year":"2010","journal-title":"Ann Dermatol Venereol"},{"key":"R48-2-20240903","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1080\/09546634.2021.1886230","article-title":"Efficacy and predictive factors of cyclosporine A in alopecia areata: A systematic review with meta-analysis","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R49-2-20240903","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/0378-6323.45216","article-title":"Trace element levels in alopecia areata","volume":"75","author":"Bhat","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R50-2-20240903","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: A systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R51-2-20240903","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1529-8019.2011.01420.x","article-title":"Systemic treatment for alopecia areata","volume":"24","author":"Otberg","year":"2011","journal-title":"Dermatol Ther"},{"key":"R52-2-20240903","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-4632.2009.04230.x","article-title":"Treatment of alopecia areata with fractional photothermolysis laser","volume":"49","author":"Yoo","year":"2010","journal-title":"Int J Dermatol"},{"key":"R53-2-20240903","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/archderm.1983.01650360021007","article-title":"PUVA treatment of alopecia areata","volume":"119","author":"Claudy","year":"1983","journal-title":"Arch Dermatol"},{"key":"R54-2-20240903","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0190-9622(85)70088-6","article-title":"Topical photochemotherapy for alopecia areata","volume":"12","author":"Mitchell","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"R55-2-20240903","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000250381","article-title":"PUVA treatment for alopecia areata","volume":"161","author":"Lassus","year":"1980","journal-title":"Dermatologica"},{"key":"R56-2-20240903","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0781.2011.00612.x","article-title":"Narrowband ultraviolet B phototherapy for alopecia areata","volume":"27","author":"Bayramg\u00fcrler","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R57-2-20240903","first-page":"327","article-title":"Medical phototherapy in childhood skin diseases","volume":"63","author":"Veith","year":"2011","journal-title":"Minerva Pediatr"},{"key":"R58-2-20240903","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1097\/00042728-200712000-00011","article-title":"308-nm excimer laser for the treatment of alopecia areata","volume":"33","author":"Al-Mutairi","year":"2007","journal-title":"Dermatol Surg"},{"key":"R59-2-20240903","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1525-1470.2009.00980.x","article-title":"308-nm excimer laser for the treatment of alopecia areata in children","volume":"26","author":"Al-Mutairi","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"R60-2-20240903","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00128071-200506060-00007","article-title":"Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: A plot study","volume":"6","author":"Sasmaz","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"R61-2-20240903","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1346-8138.2002.tb00277.x","article-title":"Onion juice (Allium cepa L.), a new topical treatment for alopecia areata","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"key":"R62-2-20240903","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2004.01.046","article-title":"Topical 5-fluorouracil is ineffective in the treatment of extensive alopecia areata","volume":"50","author":"Kaplan","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R63-2-20240903","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-4362.1998.00540.x","article-title":"Dermatography as a new treatment for alopecia areata of the eyebrows","volume":"37","author":"van der Velden","year":"1998","journal-title":"Int J Dermatol"},{"key":"R64-2-20240903","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R65-2-20240903","first-page":"S97","article-title":"Targeting of JAK3 prevents onset of murine alopecia areata. Immunology I: Adaptive immunity abstracts","volume":"132","author":"Jabbari","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R66-2-20240903","first-page":"15","article-title":"Selective JAK-nibs: Prospects in inflammatory and autoimmune diseases","volume":"33","author":"Haikarainen","year":"2019","journal-title":"Bio Drugs"},{"key":"R67-2-20240903","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"R68-2-20240903","doi-asserted-by":"crossref","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signalling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"key":"R69-2-20240903","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of Janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R70-2-20240903","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"key":"R71-2-20240903","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: A systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R72-2-20240903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"R73-2-20240903","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R74-2-20240903","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R75-2-20240903","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jdcr.2018.07.018","article-title":"Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes","volume":"4","author":"Craiglow","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R76-2-20240903","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors \u2013 A double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"key":"R77-2-20240903","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/pde.13699","article-title":"Response to ustekinumab in three pediatric patients with alopecia areata","volume":"36","author":"Aleisa","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"R78-2-20240903","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: Dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"R79-2-20240903","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2340\/00015555-3183","article-title":"Dupilumab improved alopecia areata in a patient with atopic dermatitis: A case report","volume":"99","author":"Uchida","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R80-2-20240903","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/ijt.ijt_59_19","article-title":"Apremilast in refractory alopecia areata","volume":"11","author":"Est\u00e9banez","year":"2019","journal-title":"Int J Trichology"},{"key":"R81-2-20240903","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00403-018-1876-y","article-title":"A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata","volume":"311","author":"Mikhaylov","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"R83-2-20240903","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjd.12397","article-title":"A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata","volume":"169","author":"Trink","year":"2013","journal-title":"Br J Dermatol"},{"key":"R84-2-20240903","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1941738110366385","article-title":"Platelet-rich plasma: Where are we now and where are we going?","volume":"2","author":"Cole","year":"2010","journal-title":"Sports Health"},{"key":"R85-2-20240903","first-page":"4","article-title":"Topically applied physiologically balanced growth factors: A new paradigm of skin rejuvenation","volume":"8","author":"Sundaram","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"R86-2-20240903","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1524-4725.2012.02394.x","article-title":"Autologous platelet-rich plasma: A potential therapeutic tool for promoting hair growth","volume":"38","author":"Li","year":"2012","journal-title":"Dermatol Surg"},{"key":"R87-2-20240903","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: The therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"R88-2-20240903","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/jidsymp.2015.32","article-title":"Therapy for alopecia areata in mice by stimulating the hair cycle with parathyroid hormone agonists linked to a collagen-binding domain","volume":"17","author":"Katikaneni","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R89-2-20240903","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1346-8138.2009.00647.x","article-title":"Fexofenadine hydro- chloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases","volume":"36","author":"Inui","year":"2009","journal-title":"J Dermatol"},{"key":"R90-2-20240903","doi-asserted-by":"crossref","first-page":"755","DOI":"10.5021\/ad.2017.29.6.755","article-title":"Simvastatin\/ezetimibe therapy for recalcitrant alopecia areata: An open prospective study of 14 patients","volume":"29","author":"Choi","year":"2017","journal-title":"Ann Dermatol"},{"key":"R91-2-20240903","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1567-5688(01)00010-1","article-title":"Immunosuppressive effects of statins","volume":"3","author":"Mach","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"R92-2-20240903","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4070\/kcj.2011.41.5.253","article-title":"Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients","volume":"41","author":"Oh","year":"2011","journal-title":"Korean Circ J"},{"key":"R93-2-20240903","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/dth.12215","article-title":"Combination therapy with zinc gluconate and PUVA for alopecia areata totalis: An adjunctive but crucial role of zinc supplementation","volume":"28","author":"Lux-Battistelli","year":"2015","journal-title":"Dermatol Ther"},{"key":"R94-2-20240903","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jaad.2017.07.051","article-title":"Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis","volume":"78","author":"Tsai","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R95-2-20240903","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ced.12241","article-title":"Potential relationship between the canonical Wnt signalling pathway and expression of the vitamin D receptor in alopecia","volume":"39","author":"Lim","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"R96-2-20240903","first-page":"616","article-title":"Topical calcipotriol therapy for mild-to-moderate alopecia areata: A retrospective study","volume":"14","author":"\u00c7erman","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"R97-2-20240903","doi-asserted-by":"crossref","first-page":"e12464","DOI":"10.1111\/dth.12464","article-title":"Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study","volume":"30","author":"Narang","year":"2017","journal-title":"Dermatol Ther"},{"key":"R98-2-20240903","first-page":"5285","article-title":"Vitamin D and alopecia areata: Possible roles in pathogenesis and potential implications for therapy","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"key":"R99-2-20240903","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune dis- eases","volume":"195","author":"De Luca","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"R100-2-20240903","doi-asserted-by":"crossref","first-page":"e0215206","DOI":"10.1371\/journal.pone.0215206","article-title":"Scalp bacterial shift in Alopecia areata","volume":"14","author":"Pinto","year":"2019","journal-title":"PLoS One"},{"key":"R101-2-20240903","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14728222.2018.1481504","article-title":"Alopecia areata and the gut-the link opens up for novel therapeutic interventions","volume":"22","author":"Borde","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"R102-2-20240903","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.14309\/crj.2017.107","article-title":"Hair growth in two alopecia patients after fecal microbiota transplant","volume":"4","author":"Rebello","year":"2017","journal-title":"ACG Case Rep J"},{"key":"R104-2-20240903","doi-asserted-by":"crossref","first-page":"e0161174","DOI":"10.1371\/journal.pone.0161174","article-title":"Systematic review: Adverse events of fecal microbiota transplantation","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"R105-2-20240903","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/exd.13255","article-title":"Bone marrow-derived mesenchymal stem cells prevent alopecia areata development through the inhibition of NKG2D expression: A pilot study","volume":"26","author":"Byun","year":"2017","journal-title":"Exp Dermatol"},{"key":"R106-2-20240903","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4196\/kjpp.2018.22.5.555","article-title":"Human umbilical cord blood mesenchymal stem cells engineered to overexpress growth factors accelerate outcomes in hair growth","volume":"22","author":"Bak","year":"2018","journal-title":"Korean J Physiol Pharmacol"},{"key":"R107-2-20240903","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/exd.13812","article-title":"Effects of mesenchymal stem cell therapy on alopecia areata in cellular and hair follicle organ culture models","volume":"29","author":"Kim","year":"2020","journal-title":"Exp Dermatol"},{"key":"R108-2-20240903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13287-018-0889-y","article-title":"Cellular therapy with human autologous adipose-derived adult cells of stromal vascular fraction for alopecia areata","volume":"9","author":"Anderi","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"R109-2-20240903","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41375-018-0290-y","article-title":"IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective \u03b3-chain cytokines, decreases leukemic T-cell viability","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"R110-2-20240903","first-page":"71","article-title":"Use of lasers in the treatment of alopecia areata","volume":"5","author":"Howard","year":"2016","journal-title":"Med Lasers Eng Basic Res Clini Appl"},{"key":"R111-2-20240903","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"R112-2-20240903","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2353\/ajpath.2008.061249","article-title":"Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H\/HeJ mouse model","volume":"172","author":"Nakamura","year":"2008","journal-title":"Am J Pathol"},{"key":"R113-2-20240903","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1529-8019.2011.01421.x","article-title":"Treatment of alopecia areata: \u201cWhat is new on the horizon.\u201d?","volume":"24","author":"Hordinsky","year":"2011","journal-title":"Dermatol Ther"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_28_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:02:31Z","timestamp":1787760151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_28_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_28_21","relation":{},"ISSN":["0974-7753"],"issn-type":[{"value":"0974-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}